newsfilter
← Latest News
GlobeNewswire·

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety